Global Generic Injectables For Infectious Diseases Market, By Product type (Monoclonal Antibodies, Immunoglobulin, Cytokines, Insulin, Peptide Hormones, Blood Factors, Vaccines, Small Molecule Antibiotics, Chemotherapy Agents, Others), Molecule Type (Large Molecule, Small Molecule), Application (Oncology, Infectious Diseases, Diabetes, Blood Disorders, Hormonal Disorders, Musculoskeletal Disorders, CNS Diseases, Pain Management, Cardiovascular Diseases), Route of Administration (Intramuscular, Intravenous, Subcutaneous), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Industry Trends and Forecast to 2031.
Generic Injectables for Infectious Diseases Market Analysis and Size
Generic injectables offer cost-effective alternatives to brand-name drugs. Infectious diseases, particularly in developing countries, often require large-scale treatment programs. Generic versions of essential injectable medications make it more affordable for healthcare systems to provide treatment to a broader population. Generic injectables for infectious diseases help improve access to essential medications, especially in regions with limited healthcare resources. These drugs are often used to treat diseases such as HIV, tuberculosis, malaria, and various bacterial infections that can be particularly prevalent in low-income and underserved populations.
Data Bridge Market Research analyzes that the global generic injectables for infectious diseases market, which was USD 107,419.72 million in 2023, is likely to reach USD 218,798.99 million by 2031 and is expected to undergo a CAGR of 9.3% during the forecast period of 2024 to 2031. “Hospital pharmacies” dominate the distribution channel segment of the injectables for infectious diseases market due to the growing demand for injectables for infectious diseases.
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Product type (Monoclonal Antibodies, Immunoglobulin, Cytokines, Insulin, Peptide Hormones, Blood Factors, Vaccines, Small Molecule Antibiotics, Chemotherapy Agents, Others), By Molecule Type (Large Molecule, Small Molecule), By Application (Oncology, Infectious Diseases, Diabetes, Blood Disorders, Hormonal Disorders, Musculoskeletal Disorders, CNS Diseases, Pain Management, Cardiovascular Diseases), By Route of Administration (Intramuscular, Intravenous, Subcutaneous), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America
|
|
Market Players Covered
|
DR. Reddys Laboratries Ltd (India), Baxter International (U.S.), Mylan N.A (U.S.), Teva Pharmaceuticals (Israel), Astra Zeneca Plc (U.S.), Sanofi S.A (France), Fresenius Kabi (Germany), Pfizer Inc (U.S.), Cipla Ltd (India), Merck & Co. Inc (U.S.), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd (India), Aurobindo Pharma Limited (India), Samsung Biologics Co Ltd (South Korea), Biocon (India), Lupin,Ltd (India), Astrazeneca (U.S.), GlaxoSmithKline Plc (U.K.), Hikma Pharmaceuticals (U.K.), Johnson & Johnson Services, Inc (U.S.), Sanofi SA (U.S.), Amgen Inc.(U.S.), Bristol- Myers Squibb Company (U.S.), Piramal Pharma Solutions (India), Merck KGaA (Germany)
|
|
Market Opportunities
|
|
Market Definition
The generic injectables for infectious diseases market encompasses the pharmaceutical industry segment dedicated to the production, distribution, and sale of non-branded injectable medications designed to prevent, treat, or manage infectious diseases. These medications are typically administered via injection, either intravenously (IV), intramuscularly (IM), or subcutaneously (SC), and are used to combat a wide range of infectious diseases caused by bacteria, viruses, fungi, and parasites. Infectious diseases can include conditions such as HIV/AIDS, tuberculosis, malaria, bacterial infections, and various other contagious illnesses.
Global Generic Injectables for Infectious Diseases Market Dynamics
Drivers
- Rising prevalence of infectious diseases
The high prevalence of infectious diseases, such as HIV, tuberculosis, malaria, and bacterial infections, drives the demand for injectable medications. As these diseases remain widespread, there is a continuous need for cost-effective treatments, which generic injectables provide.
- Rising innovations and competition among market players
The presence of multiple pharmaceutical companies manufacturing generic injectables fosters competition. This competition can lead to innovation in production methods, quality improvements, and price reductions, benefiting both patients and healthcare systems.
Opportunities
- Rising R&D activities
Generic manufacturers are investing in research and development to expand their product portfolios, develop bioequivalent formulations, and gain regulatory approvals for a wider range of injectable infectious disease treatments. This will create more opportunities for the growth of the market.
Restraints/Challenges
- Regulatory complexity and stringent requirements
Obtaining regulatory approvals for generic injectables can be a lengthy and costly process. Manufacturers must demonstrate bioequivalence and quality standards, which may delay market entry and increase costs.
Recent Development
- In 2022, Collaboration of Midatech Pharma and Johnson & Johnsons Pharmaceuticals in the year 2020 July. Increased drug delivery technology with the aim of bio delivery increased research and development in biodistribution
- In 2022, Hikma Pharmaceutical for the U.S. introduced the new 503B, a new sterile drug with increased business with increased effectivity, quality, injectables, and other increased medications
Global Generic Injectables for Infectious Diseases Market Scope
The generic injectables for infectious diseases market is segmented on the basis of product type, molecule type, application, route of administration, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Monoclonal Antibodies
- Immunoglobulin
- Cytokines
- Insulin
- Peptide Hormones
- Blood Factors
- Vaccines
- Small Molecule Antibiotics
- Chemotherapy Agents
- Others
Molecule Type
- Large Molecule
- Small Molecule
Application
- Oncology
- Infectious Diseases
- Diabetes
- Blood Disorders
- Hormonal Disorders
- Musculoskeletal Disorders
- CNS Diseases
- Pain Management
- Cardiovascular Diseases
Route of Administration
- Intramuscular
- Intravenous
- Subcutaneous
Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Global Generic Injectables for Infectious Diseases Market Regional Analysis/Insights
The generic injectables for infectious diseases market is analyzed and market size insights and trends are provided by country, product type, molecule type, application, route of administration, and distribution channel as referenced above.
The countries covered in the generic injectables for infectious diseases market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina and rest of South America.
North America is expected to dominate the market due to the presence of advanced healthcare infrastructure.
Asia-Pacific is expected to show significant growth during the forecast period of 2024 to 2031 due to surge in regional investments.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The generic injectables for infectious diseases market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the generic injectables for infectious diseases market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the generic injectables for infectious diseases market.
Competitive Landscape and Global Generic Injectables for Infectious Diseases Market Share Analysis
The generic injectables for infectious diseases market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the generic injectables for infectious diseases market.
Some of the major players operating in the generic injectables for infectious diseases market are:
- DR. Reddys Laboratries Ltd (India)
- Baxter International (U.S.)
- Mylan N.A (U.S.)
- Teva Pharmaceuticals (Israel)
- Astra Zeneca Plc (U.S.)
- Sanofi S.A (France)
- Fresenius Kabi (Germany)
- Pfizer Inc (U.S.)
- Cipla Ltd (India)
- Merck & Co. Inc (U.S.)
- Novartis AG (Switzerland)
- Sun Pharmaceutical Industries Ltd (India)
- Aurobindo Pharma Limited (India)
- Samsung Biologics Co Ltd (South Korea)
- Biocon (India)
- Lupin, Ltd (India)
- Astrazeneca (U.S.)
- GlaxoSmithKline Plc (U.K.)
- Hikma Pharmaceuticals (U.K.)
- Johnson & Johnson Services, Inc (U.S.)
- Sanofi SA (U.S.)
- Amgen Inc.(U.S.)
- Bristol- Myers Squibb Company (U.S.)
- Piramal Pharma Solutions (India)
- Merck KGaA (Germany)
SKU-